Help improve the information
Suggest a correction, missing detail, or peptide addition by .
Not FDA approved
This peptide is not FDA approved for human use, and because peptides are often incompletely studied you should not use or self-experiment with it outside qualified medical supervision.
Overview
Selank is a lab-made heptapeptide based on tuftsin with sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. The reviewed source set supports a real non-US intranasal drug-reference context and a modest human anxiety literature, including a randomized controlled trial, but it does not support describing Selank as a generic self-injected nootropic peptide.
Reported benefits
- Defined heptapeptide identity as a tuftsin analogue.
- Published human anxiety literature exists, including a randomized controlled trial.
- Additional preclinical and mechanistic work exists in cognition, GABA-related signaling, and gene-expression studies.
- Best-supported real-world product context in the reviewed source set is intranasal rather than injectable.
Mechanism of action
Reviewed papers discuss Selank as a multifunctional neuroactive peptide with proposed effects on GABA-related signaling, monoamine balance, gene expression (how strongly cells make specific proteins), and stress-response biology. Those mechanisms are still not fully settled, and the current source set does not justify presenting them as a single proven receptor story.
The evidence is stronger for clinical anxiolytic interest than for highly specific marketing claims about BDNF (a protein involved in brain cell growth and maintenance), dopamine optimization, or universal benzodiazepine equivalence.
Reported Use
No FDA dosing guidance
This peptide is not covered by FDA-labeled dosing guidance on this page. Peptides are often investigational or incompletely studied. Do not self-experiment; use only with a doctor or qualified clinician.
Typical dose
No source-backed casual injected-human Selank protocol was identified
Frequency
Not established
Injection sites
The better-supported product context in the reviewed source set is intranasal, not self-injected
Best timing
Not established
Effects timeline
Not established for casual injected use
Storage
Do not treat generic lyophilized-vial instructions as validated Selank protocol
Cycle length
Not established as a general-use peptide cycle
Break between
Not established
Sequence
TKPRPGP
Loading viewer
Preparing 3D peptide scene
Quick Signals
At A Glance
A faster read on evidence, focus, structure, and status.
Evidence
Mostly preclinical
The reviewed source set supports a non-US intranasal drug-reference context plus a modest human anxiety literature and…
132 indexed studiesCurrent level
Preclinical
Scale: low evidence to established use
Safety
Side Effects And Safety
Switch between common side-effect notes and stop criteria to keep safety context visible.
Reported or plausible side effects
- Nasal or local-administration irritation is a practical concern in the intranasal product context.
- Neuropsychiatric use should stay cautious, especially around mood, sedation, or concomitant psychiatric medication use.
Key cautions
- The reviewed source set does not support broad claims of universal safety or guaranteed absence of tolerance or withdrawal.
- Product identity, route, and handling quality remain important when material is sourced outside a labeled product context.
- Self-injection risk is separate from the peptide itself and should not be hidden inside generic peptide advice.
Molecule
Molecular Information
Core structure fields that help explain what kind of peptide this is and how much sequence detail is available.
Molecular weight
751.9 Da
Chain length
7 amino acids
Sequence type
Tuftsin analog
Derived from
Synthetic analogue of tuftsin
Amino acid sequence source string
Thr-Lys-Pro-Arg-Pro-Gly-Pro
None established beyond the synthetic analogue context
Context
Important Context
The main context that changes how confidently this peptide should be interpreted.
Research status
The reviewed source set supports a non-US intranasal drug-reference context plus a modest human anxiety literature and broader preclinical work.
Regulatory and sport status
FDA review shows it is not FDA approved. Source: openFDA drugsfda API. Sport review: not specifically named on current WADA list.
Route Notes
Route-Specific Notes
Only shown when the source material adds route-specific details beyond the quick-start guide.
Injectable
- Administration: No source-backed casual injected-human Selank protocol was identified.
- Absorption: No validated injectable framework was identified in the reviewed source set.
- Cycle: Not established
- Additional: The better-supported product context in the reviewed source set is intranasal.
Intranasal
- Administration: The best-supported real-world route in the reviewed source set is intranasal.
- Absorption: The reviewed source set supports intranasal use more strongly than injectable use.
- Cycle: Not established as a general-use peptide cycle
- Additional: Use the exact product or study context rather than a generic mcg quick-start.
Compare
How Well Documented Is It?
A quick five-point snapshot of how visible and well-documented this peptide is. Higher values mean more coverage or clearer status in that area, not better medical performance.
Research
How much published research coverage this peptide has in the linked sources, with an approval-context floor for clearly established drug products.
Source: PubMed
Regulatory
How clearly the approval or regulatory status is documented for this entry.
Source: openFDA drugsfda API
Sport
How clearly sports or competition status is documented in the linked review sources.
Source: WADA Prohibited List
Breadth
How broadly this peptide appears across discussion topics and use-case groupings in the catalog.
Source: Curated site taxonomy
Sequence
How much structure or residue-sequence detail is available for this entry.
Source: Sequence
Protocols
Research Protocols
Common protocol-style rows shown in a consistent table layout so every peptide page is easy to compare.
| Goal | Dose | Route | Frequency |
|---|---|---|---|
| Human anxiety studies | Study- and product-specific | Intranasal | Study-specific |
| Preclinical cognition and stress models | Model-specific | Experimental context | Study-specific |
Research
What It Has Been Studied For
Plain-language summaries of the main health areas where this peptide shows up in the linked research.
Stacking
What People Commonly Stack It With
A plain-language view of compounds that are commonly discussed alongside this peptide in the source material.
Practical
Preparation, Quality, And Expectations
Operational checklist blocks designed for quick scanning and repeatable page structure.
How to reconstitute
- •The best-supported product context in the reviewed source set is a pre-made intranasal product rather than a generic lyophilized vial.
- •No validated consumer BAC-water reconstitution protocol was identified.
- •Do not treat generic peptide-mixing advice as source-backed Selank guidance.
Quality indicators
Good signs
- Product identity clearly states Selank.
- Route and concentration are clearly labeled.
- Handling instructions match the actual formulation in hand.
Avoid
- Research-powder injection advice presented as equivalent to intranasal product use.
- Confident claims about universal benzodiazepine equivalence, no tolerance, or no withdrawal.
- Unclear route, concentration, or storage instructions.
- Vague sourcing or poor product-integrity documentation.
What to expect
No universal response timeline was established from the reviewed source set.
Human and product-context literature is better framed over days to weeks rather than as guaranteed hour-by-hour effects.
References
Research And Source List
Structured reference cards with source metadata and a direct link so users can inspect the original study/source.
PubChem compound record
PubChem CID 11765600
PubChem record supporting Selank molecular identity, formula, and molecular weight.
PubMed search
Indexed literature query
Search link for indexed publications that mention Selank.
Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia
Zh Nevrol Psikhiatr Im S S Korsakova, 2008
Randomized controlled trial reference in generalized anxiety disorder and neurasthenia.
Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment
Bulletin of Experimental Biology and Medicine, 2019
Preclinical cognition and BDNF-related paper.
Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors
Journal of Clinical Pharmacology, 2021
Review discussing Selank in the context of GABA-related agents.
Vidal Selank page
Drug reference
Current non-US intranasal product reference used for route and marketed-context review.
openFDA Selank query
FDA database
Approval-database query reviewed for Selank; no FDA-approved product match was identified.
WADA Prohibited List
WADA
Official anti-doping reference for current prohibited categories.
WADA Monitoring Program
WADA
Official monitored-substances reference reviewed alongside the prohibited list.